Cambodia’s liver cancer burden keeps rising even as age-standardized rates fall
Cambodia’s hepatocellular carcinoma burden has not moved in a straight line. Between 1990 and 2021, age-standardized rates for several major etiologies trended downward, yet the absolute number of cases and deaths continued to climb. That pattern usually points to a growing population at risk, expanding longevity, and a disease that remains embedded in the country’s underlying liver health profile.
The analysis drew on Cambodia-specific data from the Global Burden of Disease 2021 study and examined liver cancer by age, sex, etiology, incidence, prevalence, deaths, disability-adjusted life years, and attributable risk. Investigators also modeled temporal change with estimated annual percentage change to separate declining standardized rates from the heavier absolute burden that still builds over time. The result is a clearer picture of how Cambodia’s liver cancer epidemic is changing shape rather than simply shrinking.
Viral hepatitis still drives most cases, but the etiology mix is changing
For decades, HBV and HCV have remained the main drivers of liver cancer in Cambodia. Those infections continue to anchor the national burden, even as the age-standardized rates linked to HBV-, HCV-, and NAFLD-related liver cancer moved downward over the study period. Lower standardized rates suggest some improvement in risk distribution, but they do not erase the accumulated caseload already present in the population.
A sharper concern emerged around alcoholic liver disease. The age-standardized rate of alcohol-related liver cancer rose against the overall downward trend. In practical terms, alcohol is not just adding another contributor; it is reshaping the etiologic profile of liver cancer in a country where viral hepatitis still accounts for much of the baseline burden. Chronic ethanol exposure accelerates fibrosis, promotes cirrhosis, and amplifies carcinogenic signaling in hepatocytes, making the rise biologically plausible and clinically consequential.
The burden is not distributed evenly between men and women
Sex stratification revealed a persistent imbalance. The burden of HBV-related liver cancer and alcohol-related liver cancer was substantially heavier in men. By contrast, HCV-related and NAFLD-related liver cancer were more severe in women. Those patterns matter because they imply different exposure histories, different metabolic profiles, and different opportunities for prevention.
Men in Cambodia appear to shoulder the combined effects of viral infection and alcohol exposure more heavily, a pairing that can push chronic liver injury toward malignancy more quickly. Women, meanwhile, are carrying a larger share of the burden linked to HCV and fatty liver disease, conditions that often evolve more slowly but can remain silent until advanced fibrosis is established. The clinical implication is straightforward: a one-size-fits-all prevention strategy will miss important pockets of risk.
Metabolic liver disease is no longer a secondary concern
The rise of NAFLD-related liver cancer deserves particular attention. Even though the age-standardized rate for NAFLD-related disease trended downward, its contribution to the national burden continued to increase. That combination suggests a transition familiar in many countries undergoing nutritional and epidemiologic change: metabolic liver injury is gaining weight as viral hepatitis control slowly improves.
Fatty liver disease becomes oncogenic through a chain of insulin resistance, lipid toxicity, oxidative stress, and chronic low-grade inflammation. Over time, those processes can drive fibrosis and create a microenvironment favorable to malignant transformation. In a setting where HBV and HCV remain active contributors, metabolic disease does not replace the old problem. It layers on top of it.
The numbers point to prevention gaps, not just treatment gaps
The study’s most important message is not that standardized rates are declining. It is that the country still recorded a rising total burden while the etiologic structure continued to shift. That means Cambodia is living through a transition in which older infections remain dangerous, alcohol-related injury is strengthening, and metabolic disease is becoming more visible inside the liver cancer mix.
For public health planning, this argues for a strategy built around virus control, metabolic intervention, and gender stratification. Hepatitis B vaccination, hepatitis C detection and treatment, and surveillance for chronic viral carriers remain foundational. At the same time, obesity, diabetes, dyslipidemia, and other metabolic drivers cannot be treated as secondary issues when they are feeding the next wave of liver cancer risk. Alcohol reduction belongs in the same prevention frame because the upward trend in alcohol-related age-standardized burden runs directly against the broader decline seen elsewhere.
What Cambodia will need from surveillance and policy
This analysis gives policymakers a usable map of where liver cancer prevention needs to move next. Viral hepatitis still dominates the current burden, so infection control remains central. Yet the growing role of metabolic disease and the increase in alcohol-related burden suggest the country is entering a more mixed-etiology era, where prevention must extend beyond infectious disease programs alone.
Age and sex patterns should shape the response. Men need focused attention for HBV- and alcohol-related risk, while women deserve sharper surveillance for HCV- and NAFLD-related disease. A national approach that ignores those differences will misclassify risk and leave preventable cases on the table.
The study does not provide a clinical trial endpoint or an intervention effect. Its value lies in burden mapping, and the map is clear enough: Cambodia’s liver cancer challenge is still dominated by viral hepatitis, but the road ahead is being altered by alcohol and metabolic disease. The remaining question is not whether the burden will change, but whether prevention programs will change fast enough to match it.